266 related articles for article (PubMed ID: 27605873)
1. Immunological battlefield in gastric cancer and role of immunotherapies.
Wang M; Busuttil RA; Pattison S; Neeson PJ; Boussioutas A
World J Gastroenterol; 2016 Jul; 22(28):6373-84. PubMed ID: 27605873
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of gastric cancer: Past, future perspective and challenges.
Xie J; Fu L; Jin L
Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
4. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
5. The immune response in cancer: from immunology to pathology to immunotherapy.
Giraldo NA; Becht E; Vano Y; Sautès-Fridman C; Fridman WH
Virchows Arch; 2015 Aug; 467(2):127-35. PubMed ID: 26077464
[TBL] [Abstract][Full Text] [Related]
6. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Subhash VV; Yeo MS; Tan WL; Yong WP
J Immunol Res; 2015; 2015():308574. PubMed ID: 26579545
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results.
Vollmers HP; Zimmermann U; Krenn V; Timmermann W; Illert B; Hensel F; Hermann R; Thiede A; Wilhelm M; Rückle-Lanz H; Reindl L; Müller-Hermelink HK
Oncol Rep; 1998; 5(3):549-52. PubMed ID: 9538151
[TBL] [Abstract][Full Text] [Related]
8. Review: Gastric cancer: Basic aspects.
Resende C; Gomes CP; Machado JC
Helicobacter; 2020 Sep; 25 Suppl 1():e12739. PubMed ID: 32918356
[TBL] [Abstract][Full Text] [Related]
9. Gastric cancer and the epoch of immunotherapy approaches.
Niccolai E; Taddei A; Prisco D; Amedei A
World J Gastroenterol; 2015 May; 21(19):5778-93. PubMed ID: 26019442
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2016 Jan; 97():65-71. PubMed ID: 26321371
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
Tewari M; Sahai S; Mishra RR; Shukla SK; Shukla HS
Surg Oncol; 2012 Sep; 21(3):164-71. PubMed ID: 22521560
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer.
Okinaga K; Iinuma H; Kitamura Y; Yokohata T; Inaba T; Fukushima R
J Exp Clin Cancer Res; 2006 Sep; 25(3):339-49. PubMed ID: 17167974
[TBL] [Abstract][Full Text] [Related]
14. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
Singh P; Toom S; Huang Y
J Hematol Oncol; 2017 May; 10(1):105. PubMed ID: 28494772
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
Marabelle A; Gray J
Pediatr Blood Cancer; 2015 Aug; 62(8):1317-25. PubMed ID: 25808079
[TBL] [Abstract][Full Text] [Related]
16. Tricks tumors use to escape from immune control.
Whiteside TL
Oral Oncol; 2009 Oct; 45(10):e119-23. PubMed ID: 19467917
[TBL] [Abstract][Full Text] [Related]
17. Rationale for immunological approaches to breast cancer therapy.
Monnot GC; Romero P
Breast; 2018 Feb; 37():187-195. PubMed ID: 28629632
[TBL] [Abstract][Full Text] [Related]
18. Targeting adenosine in cancer immunotherapy: a review of recent progress.
Whiteside TL
Expert Rev Anticancer Ther; 2017 Jun; 17(6):527-535. PubMed ID: 28399672
[TBL] [Abstract][Full Text] [Related]
19. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
